Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial

BACKGROUND: The optimal intravenous (IV) iron would allow safe correction of iron deficiency at a single infusion over a short time. The FERWON-NEPHRO trial evaluated the safety and efficacy of iron isomaltoside 1000/ferric derisomaltose (IIM) in patients with non-dialysis-dependent chronic kidney d...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhandari, Sunil, Kalra, Philip A, Berkowitz, Mario, Belo, Diogo, Thomsen, Lars L, Wolf, Myles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771981/
https://www.ncbi.nlm.nih.gov/pubmed/32049331
http://dx.doi.org/10.1093/ndt/gfaa011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771981/
https://www.ncbi.nlm.nih.gov/pubmed/32049331
http://dx.doi.org/10.1093/ndt/gfaa011

Ejemplares similares